ADPKD
ADPKD
Part of NephTimes
Advertisement
Victoria SochaADPKD | February 8, 2024
Unilateral nephrectomy resulted in a decrease of 46.4% in urinary EGF excretion, and a decrease of 35.2% in eGFR.
Read More
Victoria SochaADPKD | February 5, 2024
Patients with autosomal dominant polycystic kidney disease commonly progress to ESRD in the fifth decade of life.
Victoria SochaADPKD | February 5, 2024
Autosomal dominant polycystic kidney disease (ADPKD) is characterized by the accumulation of fluid-filled cysts in the kidney
Victoria SochaADPKD | February 5, 2024
Results of a study evaluating the prevalence of common comorbid conditions in patients with ADPKD.
Victoria SochaADPKD | February 5, 2024
Clinical development models for polycystic kidney disease remain challenging.
Victoria SochaASN Kidney Week 2023 | February 5, 2024
Tolvaptan showed real-world effectiveness in slowing decline in eGFR when compared with matched historical controls.
Victoria SochaADPKD | February 5, 2024
Patients with autosomal dominant polycystic kidney disease commonly develop end-stage kidney disease.
Victoria SochaADPKD | February 5, 2024
First, an automated kidney volume segmentation model is used to accurately calculate htTKV.
Victoria SochaADPKD | February 5, 2024
A literature review of possible nonpharmacological therapeutic strategies to slow enlargement of cysts in ADPKD.
Victoria SochaADPKD | February 5, 2024
The CKiD equation was associated with the highest prevalence of hyperfiltration (35%).
Victoria SochaADPKD | February 5, 2024
Disease acceptance among patients with autosomal dominant polycystic kidney disease.
Victoria SochaNKF Spring Clinical Meetings 2023 | February 5, 2024
Health-related quality of life (HRQoL) is adversely affected in patients with autosomal dominant polycystic kidney ...
Victoria SochaNephrology Times | February 5, 2024
The most common renal replacement therapies for patients with end-stage renal disease (ESRD) are peritoneal dialysis and ...
Victoria SochaNephrology Times | February 5, 2024
The most common inherited kidney disease is autosomal dominant polycystic kidney disease(ADPKD). According to Shunlai ...
Victoria SochaNephrology Times | February 5, 2024
Results of previous studies have shown that tolvaptan slows expansion of kidney volume and decline in kidney function in ...
Victoria SochaADPKD | February 5, 2024
Approximately 5% to 10% of all cases of kidney failure are related to autosomal dominant polycystic kidney disease ...
Victoria SochaADPKD | February 5, 2024
According to Alexander R. Chang, MD, and colleagues, the majority of studies of autosomal dominant polycystic kidney ...
Victoria SochaASN Kidney Week 2022 | February 5, 2024
The most common monogenic nephropathy is autosomal dominant polycystic kidney disease (ADPKD). ADPKD is associated with ...
Victoria SochaADPKD | February 5, 2024
Among patients with autosomal dominant polycystic kidney disease (ADPKD), a small percentage have no clear family ...
Victoria SochaADPKD | February 5, 2024
Among patients with autosomal dominant polycystic kidney disease (ADPKD), the expected rate of decline in estimated ...
Advertisement
Advertisement
Advertisement
Latest News

February 26, 2024